PL3675879T3 - Cerebrolizyna do zastosowania w leczeniu cadasil - Google Patents
Cerebrolizyna do zastosowania w leczeniu cadasilInfo
- Publication number
- PL3675879T3 PL3675879T3 PL18759322T PL18759322T PL3675879T3 PL 3675879 T3 PL3675879 T3 PL 3675879T3 PL 18759322 T PL18759322 T PL 18759322T PL 18759322 T PL18759322 T PL 18759322T PL 3675879 T3 PL3675879 T3 PL 3675879T3
- Authority
- PL
- Poland
- Prior art keywords
- cerebrolysin
- cadasil
- treatment
- Prior art date
Links
- 208000010482 CADASIL Diseases 0.000 title 1
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 title 1
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 title 1
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17188180.8A EP3449931B1 (en) | 2017-08-28 | 2017-08-28 | Use of cerebrolysin |
| EP18759322.3A EP3675879B1 (en) | 2017-08-28 | 2018-08-28 | Cerebrolysin for use in the treatment of cadasil |
| PCT/EP2018/073106 WO2019042983A1 (en) | 2017-08-28 | 2018-08-28 | USE OF CERBROLYSINE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3675879T3 true PL3675879T3 (pl) | 2022-02-14 |
Family
ID=59745228
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17188180T PL3449931T3 (pl) | 2017-08-28 | 2017-08-28 | Zastosowanie cerebrolizyny |
| PL18759322T PL3675879T3 (pl) | 2017-08-28 | 2018-08-28 | Cerebrolizyna do zastosowania w leczeniu cadasil |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17188180T PL3449931T3 (pl) | 2017-08-28 | 2017-08-28 | Zastosowanie cerebrolizyny |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12589118B2 (pl) |
| EP (2) | EP3449931B1 (pl) |
| JP (1) | JP7281450B2 (pl) |
| KR (1) | KR102676274B1 (pl) |
| CN (1) | CN111050780B (pl) |
| AU (1) | AU2018326339A1 (pl) |
| CA (1) | CA3073991A1 (pl) |
| EA (1) | EA202090108A1 (pl) |
| ES (2) | ES2767070T3 (pl) |
| HR (1) | HRP20200031T1 (pl) |
| MX (1) | MX2020002267A (pl) |
| PH (1) | PH12020500376A1 (pl) |
| PL (2) | PL3449931T3 (pl) |
| UA (1) | UA129400C2 (pl) |
| WO (1) | WO2019042983A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220168325A1 (en) * | 2019-03-25 | 2022-06-02 | The University Of Vermont | Methods to promote cerebral blood flow in the brain |
| ES2964145T3 (es) | 2020-07-13 | 2024-04-04 | Ever Neuro Pharma Gmbh | Método para producir un hidrolizado de proteína de cerebro de mamífero |
| KR20240159455A (ko) * | 2021-06-02 | 2024-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 신경성 유전자좌 노치 상동체 단백질 3(notch3) 제제를 이용한 뇌혈관 질환의 치료 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69126563T2 (de) | 1990-04-12 | 1998-02-05 | Ebewe Arzneimittel | Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia |
| EP1857463A1 (en) * | 2006-05-03 | 2007-11-21 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Peptide having neuroprotective effects |
| CA2734646C (en) | 2008-08-20 | 2016-06-28 | James W. Mcginity | Hot-melt extrusion of modified release multi-particulates |
-
2017
- 2017-08-28 PL PL17188180T patent/PL3449931T3/pl unknown
- 2017-08-28 EP EP17188180.8A patent/EP3449931B1/en active Active
- 2017-08-28 ES ES17188180T patent/ES2767070T3/es active Active
-
2018
- 2018-08-28 US US16/642,307 patent/US12589118B2/en active Active
- 2018-08-28 UA UAA202001881A patent/UA129400C2/uk unknown
- 2018-08-28 CA CA3073991A patent/CA3073991A1/en active Pending
- 2018-08-28 EP EP18759322.3A patent/EP3675879B1/en active Active
- 2018-08-28 ES ES18759322T patent/ES2901508T3/es active Active
- 2018-08-28 JP JP2020512835A patent/JP7281450B2/ja active Active
- 2018-08-28 CN CN201880055542.5A patent/CN111050780B/zh active Active
- 2018-08-28 PL PL18759322T patent/PL3675879T3/pl unknown
- 2018-08-28 KR KR1020207007069A patent/KR102676274B1/ko active Active
- 2018-08-28 AU AU2018326339A patent/AU2018326339A1/en not_active Abandoned
- 2018-08-28 EA EA202090108A patent/EA202090108A1/ru unknown
- 2018-08-28 MX MX2020002267A patent/MX2020002267A/es unknown
- 2018-08-28 WO PCT/EP2018/073106 patent/WO2019042983A1/en not_active Ceased
-
2020
- 2020-01-09 HR HRP20200031TT patent/HRP20200031T1/hr unknown
- 2020-02-26 PH PH12020500376A patent/PH12020500376A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3449931A1 (en) | 2019-03-06 |
| HRP20200031T1 (hr) | 2020-03-20 |
| EP3675879B1 (en) | 2021-09-15 |
| CN111050780A (zh) | 2020-04-21 |
| WO2019042983A1 (en) | 2019-03-07 |
| CN111050780B (zh) | 2023-11-03 |
| KR20200045503A (ko) | 2020-05-04 |
| PH12020500376A1 (en) | 2020-12-07 |
| EA202090108A1 (ru) | 2020-03-31 |
| PL3449931T3 (pl) | 2020-06-01 |
| CA3073991A1 (en) | 2019-03-07 |
| MX2020002267A (es) | 2020-10-22 |
| EP3449931B1 (en) | 2019-10-16 |
| US20200376040A1 (en) | 2020-12-03 |
| ES2767070T3 (es) | 2020-06-16 |
| JP2020531568A (ja) | 2020-11-05 |
| JP7281450B2 (ja) | 2023-05-25 |
| US12589118B2 (en) | 2026-03-31 |
| ES2901508T3 (es) | 2022-03-22 |
| EP3675879A1 (en) | 2020-07-08 |
| AU2018326339A1 (en) | 2020-03-05 |
| KR102676274B1 (ko) | 2024-06-18 |
| UA129400C2 (uk) | 2025-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269462A (en) | MDM2 inhibitors and therapeutic methods that use them | |
| SI3675854T1 (sl) | Derivati piperidinil-indola za uporabo v zdravljenju glomerulopatije c3 | |
| IL290150A (en) | Compounds and methods for treating chronic pain | |
| GB201411496D0 (en) | Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy | |
| SG11201609254YA (en) | Therapeutic placental compositions, methods of making and methods of use | |
| SMT202100459T1 (it) | Azasetron per l’uso nel trattamento della perdita dell’udito | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| PL3215157T3 (pl) | Apilimod do stosowania w leczeniu czerniaka | |
| ZA201704726B (en) | Peptides and their use in the treatment of skin | |
| GB201417163D0 (en) | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | |
| GB2581876B (en) | Compositions for use in the treatment of endometrial disorder | |
| LT3373922T (lt) | Kompozicijos ir būdai skirti naudoti homocistinurijos gydyme | |
| GB201700526D0 (en) | Therapeutic use | |
| IL246855A0 (en) | Materials for use in the treatment of retinitis | |
| SG11201704486TA (en) | Improvements in and relating to the treatment of matrices and/or the contents of matrices | |
| ZA201900984B (en) | Methods and compositions for the treatment of warts | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| PL3377089T3 (pl) | Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| EP3648789C0 (en) | MTMR2-S POLYPEPTIDE FOR USE IN THE TREATMENT OF MYOPATHY | |
| ZA201802201B (en) | Novel formulation and treatment methods | |
| PT3548006T (pt) | Composição para utilização no tratamento de alterações intestinais | |
| ZA201801788B (en) | Lysobactin for use in the treatment of bovine mastitis | |
| HK1248110A1 (en) | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases | |
| GB201511772D0 (en) | Improvements in the treatment of ash |